Communications Biology (Mar 2021)

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

  • Romain Darrigrand,
  • Alison Pierson,
  • Marine Rouillon,
  • Dolor Renko,
  • Mathilde Boulpicante,
  • David Bouyssié,
  • Emmanuelle Mouton-Barbosa,
  • Julien Marcoux,
  • Camille Garcia,
  • Michael Ghosh,
  • Mouad Alami,
  • Sébastien Apcher

DOI
https://doi.org/10.1038/s42003-021-01801-2
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 14

Abstract

Read online

Darrigrand, Pierson et al. study the effect of mRNA splicing inhibitors on the generation of the MHC class I ligands. They developed a derivative of the spliceosome inhibitor isoginkgetin which is less toxic and more effective at enhancing antigen presentation and CD8+ T cell activation and showed greater antitumour activity in vivo. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.